List of Figures
Figure 1: Non-Small Cell Lung Cancer Market, Global, Molecular Characteristic Frequency (%), 2014
Figure 2: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Late-Stage Treatment Algorithm, 2014
Figure 3: Non-Small Cell Lung Cancer Market, Global, Squamous Late-Stage Treatment Algorithm, 2014
Figure 4: NSCLC, Global, Marketed Products Heatmap, 2013
Figure 5: Non-Small Cell Lung Cancer, Global, Pipeline Summary, 2014
Figure 6: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Overview, 2014
Figure 7: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Breakdown, 2014
Figure 8: Non-Small Cell Lung Cancer, Global, Clinical Trial Attrition Rates (%), 2006–2014
Figure 9: Non-Small Cell Lung Cancer, Global, Clinical Trial Mechanism of Action Failure Rates by Phase (%), 2006–2014
Figure 10: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration (months), 2006–2013
Figure 11: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Molecule Type (months), 2006–2013
Figure 12: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Mechanism of Action (months), 2006–2013
Figure 13: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product (participants), 2006–2013
Figure 14: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2013
Figure 15: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Mechanism of Action (months), 2006–2013
Figure 16: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoints, 2006–2013
Figure 17: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoint Combinations by Phase (%), 2006–2013
Figure 18: Non-Small Cell Lung Cancer Pipeline, Global, Custirsen Annual Sales ($m), 2018–2020
Figure 19: Non-Small Cell Lung Cancer Pipeline, Global, Halaven Annual Sales ($m), 2016–2020
Figure 20: Non-Small Cell Lung Cancer Pipeline, Global, Dacomitinib Annual Sales ($m), 2014–2020
Figure 21: Non-Small Cell Lung Cancer Pipeline, Global, Vargatef Annual Sales ($m), 2015–2020
Figure 22: Non-Small Cell Lung Cancer Pipeline, Global, Necitumumab Annual Sales ($m), 2015–2020
Figure 23: Non-Small Cell Lung Cancer Pipeline, Global, Ganetespib Annual Sales ($m), 2016–2020
Figure 24: Non-Small Cell Lung Cancer Pipeline, Global, Zykadia Annual Sales ($m), 2014–2020
Figure 25: Non-Small Cell Lung Cancer Pipeline, Global, Yervoy Annual Sales ($m), 2015–2020
Figure 26: Non-Small Cell Lung Cancer Pipeline, Global, Nivolumab Annual Sales ($m), 2015–2020
Figure 27: Non-Small Cell Lung Cancer Pipeline, Global, Cyramza Annual Sales ($m), 2015–2020
Figure 28: Non-Small Cell Lung Cancer Pipeline, Global, Tavocept Annual Sales ($m), 2017–2020
Figure 29: Non-Small Cell Lung Cancer Pipeline, Global, Tertomotide Annual Sales ($m), 2017–2020
Figure 30: Non-Small Cell Lung Cancer Pipeline, Global, Lucanix Annual Sales ($m), 2016–2020
Figure 31: Non-Small Cell Lung Cancer , Global, Safety and Efficacy Heatmap, 2013
Figure 32: Non-Small Cell Lung Cancer , Global, Marketed Products Heatmap, 2013
Figure 33: Non-Small Cell Lung Cancer Market, Global, Product Competitiveness Framework, 2014
Figure 34: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Future Treatment Algorithm 2020
Figure 35: Non-Small Cell Lung Cancer Market, Global, Squamous Future Treatment Algorithm
Figure 36: Non-Small Cell Lung Cancer Market, Global, Treatment Patterns (‘000), 2013–2020
Figure 37: Non-Small Cell Lung Cancer Market, Global, Market Size ($bn), 2013–2020
Figure 38: Non-Small Cell Lung Cancer Market, North America, Treatment Usage Patterns (‘000), 2013–2020
Figure 39: Non-Small Cell Lung Cancer Market, North America, Annual Cost of Treatment ($), 2013–2020
Figure 40: Non-Small Cell Lung Cancer Market, North America, Market Size, 2013–2020
Figure 41: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Treatment Patterns (‘000), 2013–2020
Figure 42: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020
Figure 43: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Market Size ($m), 2013–2020
Figure 44: Non-Small Cell Lung Cancer Market, Japan, Treatment Usage Patterns (‘000), 2013–2020
Figure 45: Non-Small Cell Lung Cancer Market, Japan, Annual Cost of Treatment ($), 2013–2020
Figure 46: Non-Small Cell Lung Cancer Market, Japan, Market Size ($bn), 2013–2020
Figure 47: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Region, 2006–2014
Figure 48: Non-Small Cell Lung Cancer, Global, Number of Co-Development Deals, 2006–2014
Figure 49: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Phase, 2006–2014
Figure 50: Non-Small Cell Lung Cancer, Global, Licensing Deals by Region, 2006–2014
Figure 51: Non-Small Cell Lung Cancer, Global, Number of Licensing Deals, 2006–2014
Figure 52: Non-Small Cell Lung Cancer, Global, Licensing Deals by Phase, 2006–2014